Low-dose aspirin reduces uteroplacental vascular impedance in early and mid gestation in IVF and ICSI patients: a randomized, placebo-controlled double-blind study

2008 ◽  
Vol 32 (5) ◽  
pp. 687-693 ◽  
Author(s):  
M. Haapsamo ◽  
H. Martikainen ◽  
J. Räsänen
Keyword(s):  
Low Dose ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Vascular Impedance ◽  
Dose Aspirin ◽  
Low Dose Aspirin

scholarly journals Low-dose aspirin does not improve ovarian responsiveness or pregnancy rate in IVF and ICSI patients: a randomized, placebo-controlled double-blind study

2005 ◽  
Vol 20 (8) ◽  
pp. 2211-2214 ◽  
Author(s):  
M. Päkkilä ◽  
J. Räsänen ◽  
S. Heinonen ◽  
H. Tinkanen ◽  
L. Tuomivaara ◽  
...  
Keyword(s):  
Pregnancy Rate ◽  
Low Dose ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism

2015 ◽  
Vol 114 (09) ◽  
pp. 645-650 ◽  
Author(s):  
Rupert Bauersachs ◽  
Jan Beyer-Westendorf ◽  
Henri Bounameaux ◽  
Timothy Brighton ◽  
Alexander Cohen ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Anticoagulant Therapy ◽  
Low Dose ◽  
Double Blind ◽  
Once Daily ◽  
Safety Outcome ◽  
Dose Aspirin ◽  
Recurrent Venous Thromboembolism ◽  
Low Dose Aspirin ◽  
Recurrent Vte

SummaryPatients with unprovoked venous thromboembolism (VTE) are at high risk for recurrence. Although rivaroxaban is effective for extended VTE treatment at a dose of 20 mg once daily, use of the 10 mg dose may further improve its benefit-to-risk ratio. Low-dose aspirin also reduces rates of recurrent VTE, but has not been compared with anticoagulant therapy. The EINSTEIN CHOICE study is a multicentre, randomised, double-blind, active-controlled, event-driven study comparing the efficacy and safety of two once daily doses of rivaroxaban (20 and 10 mg) with aspirin (100 mg daily) for the prevention of recurrent VTE in patients who completed 6–12 months of anticoagulant therapy for their index acute VTE event. All treatments will be given for 12 months. The primary efficacy objective is to determine whether both doses of rivaroxaban are superior to aspirin for the prevention of symptomatic recurrent VTE, while the principal safety outcome is the incidence of major bleeding. The trial is anticipated to enrol 2,850 patients from 230 sites in 31 countries over a period of 27 months. In conclusion, the EINSTEIN CHOICE study will provide new insights into the optimal antithrombotic strategy for extended VTE treatment by comparing two doses of rivaroxaban with aspirin (clinicaltrials.gov NCT02064439).

Subjective Experience and D2Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study

2003 ◽  
Vol 160 (2) ◽  
pp. 303-309 ◽  
Author(s):  
Lieuwe de Haan ◽  
Marion van Bruggen ◽  
Jules Lavalaye ◽  
Jan Booij ◽  
Peter M.A.J. Dingemans ◽  
...  
Keyword(s):  
Subjective Experience ◽  
Low Dose ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Recent Onset
Sign in / Sign up

Export Citation Format

Share Document